首页|期刊导航|Genes & Diseases|Novel PIK3CG compound heterozygous variants cause inactivated PI3Kγsyndrome presenting as necrotizing enterocolitis in a preterm infant

Novel PIK3CG compound heterozygous variants cause inactivated PI3Kγsyndrome presenting as necrotizing enterocolitis in a preterm infantOA

中文摘要

Inactivated phosphoinositide 3-kinase gamma(PI3Kγ)syndrome(IPGS;OMIM#619802),an autosomal recessive immunologic disorder first described by Takeda et al in 2019,classically manifests in childhood with recurrent infections,pneumonia,and colitis.1 This disorder is caused by biallelic loss-of-function variants in the PIK3CG(OMIM*601,232),located at 7q22.3.

Wenting Zhang;Xiaoying Zhou;Bixia Zheng;Xinyi Yang;Yongcheng Ni;Dong Zhou;Chunli Wang

Central Laboratory of Pediatrics,Affiliated Changzhou Children''s Hospital of Nantong University,Changzhou,Jiangsu 213003,China Pharmaceutical Laboratory,Asthma and Bronchitis Research Center of Changzhou,Changzhou,Jiangsu 213003,ChinaCentral Laboratory of Pediatrics,Affiliated Changzhou Children''s Hospital of Nantong University,Changzhou,Jiangsu 213003,China Department of Neonatology,Affiliated Changzhou Children''s Hospital of Nantong University,Changzhou,Jiangsu 213003,ChinaNanjing Key Laboratory of Pediatrics,Children''s Hospital of Nanjing Medical University,Nanjing,Jiangsu 210008,ChinaCentral Laboratory of Pediatrics,Affiliated Changzhou Children''s Hospital of Nantong University,Changzhou,Jiangsu 213003,ChinaDepartment of Pediatric Intensive Care,Affiliated Changzhou Children''s Hospital of Nantong University,Changzhou,Jiangsu 213003,ChinaCentral Laboratory of Pediatrics,Affiliated Changzhou Children''s Hospital of Nantong University,Changzhou,Jiangsu 213003,ChinaNanjing Key Laboratory of Pediatrics,Children''s Hospital of Nanjing Medical University,Nanjing,Jiangsu 210008,China

医药卫生

Necrotizing enterocolitisInactivated PI K syndromePreterm infantIPGSPik cgBiallelic loss function variantsPhosphoinositide kinase gammaCompound heterozygous variants

《Genes & Diseases》 2026 (2)

P.46-49,4

supported by the China Postdoctoral Science Foundation(No.2021M700546)Changzhou Sci&Tech Program(China)(No.CE20235066,CE20225052)Key project of Changzhou Medical Center Affiliated to Nanjing Medical University(China)(No.CMCM202314)Clinical Research Project of Nantong University(China)(No.2019LY029).

10.1016/j.gendis.2025.101618

评论